A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 4174-4176

  Rocha, Eleusa Maria F ^a   Garcia Effron, Guillermo ^a   Park, Steven ^a   Perlin, David S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; GLUCAN SYNTHASE; PROLINE; PROTEIN FKS1P; SERINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA; DRUG MECHANISM; ENZYME MODIFICATION; FUNGAL STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ASPERGILLUS FUMIGATUS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; MOLECULAR SEQUENCE DATA; PROLINE; SEQUENCE HOMOLOGY, AMINO ACID; SERINE;

EID: 35848964834     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00917-07     Document Type: Article

References (22)

1. Aleksenko, A., and A. J. Clutterbuck. 1996. The plasmid replicator AMA1 in Aspergillus nidulans is an inverted duplication of a low-copy-number dispersed genomic repeat. J. Mol. Microbiol. 19:565-574.
2. Aleksenko, A., and A. J. Clutterbuck. 1997. Autonomous plasmid replication in Aspergillus nidulans AMA1 and MATE elements. Fungal Genet. Biol. 21:373-387.
3. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
4. KU80 mutant deficient for nonhomologous end joining is a powerful tool for analyzing pathogenicity in Aspergillus fumigatus. Eukaryot. Cell 5:207-211.
5. Denning, D. W. 2006. Aspergillus and aspergillosis - progress on many fronts. Med. Mycol. 44(Suppl.):1.
6. Denning, D. W. 2002. Echinocandins: a new class of antifungal. J. Antimicrob. Chemother. 49:889-891.
7. Douglas, C. M., F. Foor, J. A. Marrinan, N. Morin, J. B. Nelsen, A. M. Dahl, P. Mazur, W. Baginasky, W. Li, M. El-Sherbeini, J. A. Clemas, S. M. Mandala, B. R. Frommer, and M. B. Kurtz. 1994. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. Proc. Natl. Acad. Sci. USA 91:12907-12911.
8. Douglas, C. M., J. A. Marrinan, W. Li, and M. B. Kurtz. 1994. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-β-D-glucan synthase activity. J. Bacteriol. 176:5686-5696.
9. Douglas, C. M., J. A. D'Ippolito, G. J. Shei, M. Meinz, J. Onishi, J. A. Marrinan, W. Li, G. K. Abruzzo, A. Flattery, K. Bartizal, A. Mitchell, and M. B. Kurtz. 1997. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 41:2471-2479.
10. Hakki, M., J. F. Staab, and K. A. Marr. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50:2522-2524.
11. Hope, W. W., S. Shoham, and T. J. Walsh. 2007. The pharmacology and clinical use of caspofungin. Exp. Opin. Drug Metab. Toxicol. 3:263-274.
12. Kurtz, M. B., G. Abruzzo, A. Flattery, K. Bartizal, J. A. Marrinan, W. Li, J. Milligan, K. Nollstadt, and C. M. Douglas. 1996. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immun. 64:3244-3251.
13. Kurtz, M. B., and C. M. Douglas. 1997. Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. 35:79-86.
14. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorns, J. Onishi, and C. M. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
15. Laverdiere, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
16. Liu, W., G. S. May, M. S. Lionakis, E. R. Lewis, and P. Kontoyiannis. 2004. Extra copies of the Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus. Antimicrob. Agents Chemother. 48:2490-2496.
17. Miller, C. D., B. W. Lomaestro, S. Park, and D. S. Perlin. 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26:877-880.
18. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
19. Paderu, P., G. Garcia-Effron, S. Balashov, G. Delmas, S. Park, and D. S. Perlin. 2007. Serum differentially alters the antifungal properties echinocandin drugs. Antimicrob. Agents Chemother. 51:2253-2256.
20. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
21. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Res. Updates 10:121-130.
22. Vehreschild, J. J., T. Kummerle, M. Karthaus, and O. A. Comely. 2007. Anidulafungin - state of affairs from a clinical perspective. Mycoses 50:38-43.